

**Purpose**

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

**Product**

**Name of Product:** Pacific North American Opportunities USD R3 Accumulating  
**PRIIP Manufacturer & Management Company:** Waystone Management Company (IE) Limited  
**Investment Manager:** Pacific Capital Partners Limited  
**ISIN:** IE000NXTFTQ8  
 Website: [www.pacificam.co.uk](http://www.pacificam.co.uk)  
 Call +44 (0)20 3970 3100 for more information.  
 The Central Bank of Ireland (CBI) is responsible for supervising Waystone Management Company (IE) Limited in relation to this Key Information Document.  
 The Product is a sub-fund of Pacific Capital UCITS Funds plc (the Company) which is authorised in Ireland and regulated by the CBI and has been registered for sale in other EEA Member States.  
 Waystone Management Company (IE) Limited is authorised in Ireland and regulated by the CBI.  
 Pacific Capital Partners Limited is authorised in England and regulated by the Financial Conduct Authority.  
**This Key Information Document is accurate as at 1 January 2025.**

**What is this product?**

**Type**  
UCITS

**Term**  
 The Company is an open-ended fund with no specified maturity date. Subject to the liquidation, dissolution and termination rights of the board of the Fund as set forth in the Fund prospectus, the Fund cannot be automatically terminated. The PRIIPs Manufacturer, Waystone Management Company (IE) Limited, is not entitled to terminate the product unilaterally.

**Objectives**  
 The investment objective of the Product is to achieve long-term capital appreciation by investing primarily in North American equity securities. The Product is a concentrated long-only fund which will primarily invest in North American equities and equity related securities listed on Recognised Markets. The Product will be primarily invested in companies domiciled in the United States but may also take exposure to companies domiciled in Canada and, to a lesser extent, Mexico. Investments shall be in the shares, common stock or other equity instruments issued by such companies, although the Product may from time to time invest in equity linked instruments (such as warrants, rights issues, convertible preferred shares and convertible bonds), depositary receipts, financial derivative instruments, other collective investment schemes or other instruments described in further detail herein. The Product is actively managed and does not intend to track any benchmark nor is it constrained by any index. The Product will typically invest in companies with a market capitalization greater than USD100 million at the time of initial purchase of the relevant security. The Investment Manager aims to achieve performance through owning a limited number of concentrated investments. In that regard, the Investment Manager typically forms a portfolio of 25-35 stocks but can hold up to 60 different stocks, depending on market conditions and opportunities. The Product's will have no industrial or sectoral focus. The Product may have exposure to entities which are not domiciled in North America or listed on Recognised Markets in North America but which derive a minimum portion of 15% of their revenues from activities in North America. The exposure obtained in this manner shall not exceed 15% of the Net Asset Value of the Product. While it is not anticipated to be a significant part of the Product's investment strategy, the Product may invest up to 15% of Net Asset Value in New Issues. A "New Issue" is an initial public offering of an equity security sold or

distributed by a member of the Financial Industry Regulatory Authority ("FINRA"). The Product may also invest up to 10% of its net assets in Rule 144A securities. Rule 144A Securities are securities that are not required to be registered for re-sale in the United States under an exemption pursuant to Section 144A of the U.S. Securities Act of 1933, but can be sold in the United States to certain institutional buyers. While the Product will primarily invest in North American equity securities and/or through financial derivative instruments, it may also invest in open-ended collective investment schemes, including exchange traded funds ("ETFs", which are typically open-ended funds, listed on a Recognised Market). The Product may use derivatives, including total return swaps, stock options and convertible bonds, for investment purposes / and or efficient portfolio management purposes. Further information in respect of the Product's use of derivatives is set out in the Financial Derivative Instruments section of the Product's Supplement. The Base Currency of the Product is USD. This Class is denominated in USD. Income from investments in the Product is not distributed but will be retained in the Product.

**Intended Retail Investor**  
 This Product is intended for investors who understand the degree of risk, who can tolerate a medium to high level of volatility and who are able to bear any losses (which may equal the whole amount invested) that may result from an investment in the Product. The Product is designed to form part of a portfolio of investments.

**Important Information**  
 - The Company is an investment company with variable capital incorporated in Ireland with registered number 553111 and established as an umbrella fund with segregated liability between sub-funds.  
 - The Company's Depository is Citi Depository Services Ireland Designated Activity Company.  
 - Further information about the Company, the Product and the different classes of shares (including a copy of the current Prospectus, the Supplement and most recent Report and Financial Statements) are available online at [www.pacificam.co.uk](http://www.pacificam.co.uk).  
 - Investors may switch shares in the Product for shares in other sub-funds of Pacific Capital UCITS Funds plc provided that they satisfy the criteria applicable to investments in the other sub-fund(s). Further information on switching is contained in the Prospectus and the Supplement.

**What are the risks and what could I get in return?**

**Risk Indicator**



The risk indicator assumes that you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less. The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you. We have classified this product as 5 out of 7, which is a medium-high risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact our capacity to pay you. Due to effects of unusual market conditions, other risks could be triggered, refer to "Risk Considerations" in the Prospectus and Supplement. This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

## Performance Scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable benchmark over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

The unfavourable scenario occurred for an investment in the product/its proxy between December 2021 and December 2024.

The moderate scenario occurred for an investment in the product/its proxy between July 2019 and July 2024.

The favourable scenario occurred for an investment in the proxy between October 2016 and October 2021.

Recommended holding period: 5 years.

Example Investment: USD 10,000.

Scenarios		If you exit after 1 year	If you exit after 5 years
<b>Minimum</b>	<b>There is no minimum guaranteed return. You could lose some or all of your investment.</b>		
Stress	What you might get back after costs	850 USD	2,260 USD
	Average return each year	-91.49 %	-25.76 %
Unfavourable	What you might get back after costs	8,190 USD	10,740 USD
	Average return each year	-18.11 %	1.44 %
Moderate	What you might get back after costs	11,350 USD	17,840 USD
	Average return each year	13.49 %	12.28 %
Favourable	What you might get back after costs	15,640 USD	23,790 USD
	Average return each year	56.35 %	18.93 %

## What happens if Waystone Management Company (IE) Limited is unable to pay out?

The Management Company has no obligation to pay out since the Company design does not contemplate any such payment being made. You are not covered by any national compensation scheme. To protect you, the assets are held with a separate company, a depository. Should the Company default, the depository would liquidate the investments and distribute the proceeds to the investors. In the worst case, however, you could lose your entire investment.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year, you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- USD 10,000 is invested.

	If you exit after 1 year	If you exit after 5 years
Total costs	100 USD	910 USD
Annual cost impact (*)	1.0%	1.1% each year

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 13.4% before costs and 12.3% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

### Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	0% of the amount you pay in when entering this investment	0 USD
Exit costs	We do not charge an exit fee for this Product.	0 USD
<b>Ongoing costs [taken each year]</b>		
Management fees and other administrative or operating costs	0.8% of the value of your investment per year. This is an estimate based on actual costs over the last year.	77 USD
Transaction costs	0.2% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	23 USD
<b>Incidental costs taken under specific conditions</b>		
Performance fees	There is no performance fee for this Product.	0 USD

## How long should I hold it and can I take money out early?

### Recommended holding period: 5 years

This Product should be considered a medium to long term investment. This means at least 5 years or more. You can sell your shares in the product on any Dealing Day as defined in the Prospectus, by using one of the methods described in the Prospectus. No exit fees will be charged. Please refer to the 'Composition of Costs' table for more information.

## How can I complain?

You can send your complaint to the Management Company at 35 Shelbourne Rd, Ballsbridge, IE - Dublin, D04 A4E0, Ireland or by e-mail to [complianceeurope@waystone.com](mailto:complianceeurope@waystone.com).

If you have a complaint about the person that advised you about this product, or who sold it to you, they will tell you where to complain.

## **Other relevant information**

- The Net Asset Value per share, past performance and 10 year performance scenarios for the Product are available at [www.pacificam.co.uk](http://www.pacificam.co.uk).
- The Product is subject to Irish taxation legislation which may have an impact on your personal tax position as an investor in the Product. Investors should consult their own tax advisers before investing in the Product.
- The details of the up-to-date remuneration policy of the Management Company, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of the persons responsible for awarding the remuneration and benefits, including the composition of the remuneration committee, are available on [www.waystone.com/waystone-policies/](http://www.waystone.com/waystone-policies/), a paper copy will be made available free of charge upon request.